Physician profile
Ann E Grady
NPI 1689676876
$3,801.13
in general payments reported to CMS, 2019-2025
31 companies · $44.98 in 2025
The $44.98 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,195 · 2020: $438 · 2021: $25.53 · 2023: $66.44 · 2024: $31.12 · 2025: $44.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $373.99 | 2019-2025 | |
| Astellas Pharma US INC | $288.15 | 2019 | |
| Novo Nordisk INC | $285.94 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $276.47 | 2019-2020 | |
| Amgen INC. | $274.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.50 | 2019-2020 | |
| Amarin Pharma, INC. | $243.71 | 2019-2020 | |
| Glaxosmithkline, LLC. | $217.17 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $207.49 | 2019-2020 | |
| Abbvie INC. | $173.92 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $145.92 | 2019 | |
| Lilly USA, LLC | $145.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $138.48 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.96 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $96.20 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $71.96 | 2019 | |
| Eisai INC. | $66.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $59.51 | 2019-2023 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $59.10 | 2019 | |
| Boston Scientific Corporation | $56.59 | 2019 | |
| Mylan Specialty L.P. | $48.13 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $46.47 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $27.28 | 2019 | |
| Edwards Lifesciences Corporation | $26.34 | 2025 | |
| Exact Sciences Corporation | $15.98 | 2024 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $15.86 | 2019 | |
| Circassia INC. | $15.71 | 2019 | |
| Genzyme Corporation | $15.70 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.57 | 2020 | |
| Zyla Life Sciences, INC. | $12.93 | 2019 | |
| Allergan, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Grady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.